t h o m s o n s c i e n t i f i c ann wescott april 8, 2008 prous science update sla dpht spring...
TRANSCRIPT
T H O M S O N S C I E N T I F I C
Ann WescottApril 8, 2008
Prous Science Update
SLA DPHT Spring Meeting 2008
Copyright 2008 Thomson Corporation 2
T H O M S O N S C I E N T I F I C
Integrity Foundations
• Launched in 2001; building on more than 40 years’ experience:– Scientific Journals: Drugs of the Future, Drug Data Report, Drugs of
Today, Drug News & Perspectives, Methods and Findings in Experimental and Clinical Pharmacology
– Databases: CIPSLINE, MDDR, Drug Data Report on CD-ROM, Trilogy, Ensemble, MFline, Synthline, DailyDrugNews.com
• More than a pipeline database: Targets & Pathways, Genomics, Synthesis, Experimental Pharmacology, PK, Metabolism, Clinical Studies, Disease Briefings
• And more to come: Predictive Pharmacology Module, IntegrityChannel, …
• Integrity core values: Coherence, consistency, curation, integration
Copyright 2008 Thomson Corporation 3
T H O M S O N S C I E N T I F I C
Integrity Content April 2008
Number of Records
278,000 (94% with chemical structure)
2,050 target records
7,700 gene records
18,500 schemes; 75,000 intermediates
691,000 values
356,000 values
84,000 records
98 executive reports
2,460 companies
820,000 references
105,000 patent families
Knowledge Area
• Drugs & Biologics
• Targets & Pathways
• Genomics
• Organic Synthesis
• Experimental Pharmacology
• Pharmacokinetics / Metabolism
• Clinical Studies
• Disease Briefings
• Companies & Research Inst.
• Literature
• Patents
Copyright 2008 Thomson Corporation 4
T H O M S O N S C I E N T I F I C
Integrity Content Growth 2007-2008
Copyright 2008 Thomson Corporation 5
T H O M S O N S C I E N T I F I C
Integrity Content Growth 2002-2008
Copyright 2008 Thomson Corporation 6
T H O M S O N S C I E N T I F I C
Integrity Evolution
• Integrity is continuously evolving and growing:
– 2002: 3 new releases, 12 major enhancements
– 2003: 2 new releases, 14 major enhancements
– 2004: 2 new releases, 6 major enhancements
– 2005: 3 new releases, 18 major enhancements
– 2006: 3 new releases, 10 major enhancements
– 2007: 4 new releases, 11 major enhancements
– 2008: 3 new releases, …
Copyright 2008 Thomson Corporation 7
T H O M S O N S C I E N T I F I C
Key New Features 2007
• New Knowledge Areas
• New product search & display fields by client request
• Related criteria searching
• Integrity Reports
• New search options from Integrity Home Page
• Patents Knowledge Area additions
• Filter by Statistics/Chart enhancements
• More structure search options in Organic Synthesis
• Integrity Metrics
Copyright 2008 Thomson Corporation 8
T H O M S O N S C I E N T I F I C
Copyright 2008 Thomson Corporation 9
T H O M S O N S C I E N T I F I C
Copyright 2008 Thomson Corporation 10
T H O M S O N S C I E N T I F I C
Copyright 2008 Thomson Corporation 11
T H O M S O N S C I E N T I F I C
Copyright 2008 Thomson Corporation 12
T H O M S O N S C I E N T I F I C
Copyright 2008 Thomson Corporation 13
T H O M S O N S C I E N T I F I C
Copyright 2008 Thomson Corporation 14
T H O M S O N S C I E N T I F I C
Copyright 2008 Thomson Corporation 15
T H O M S O N S C I E N T I F I C
Copyright 2008 Thomson Corporation 16
T H O M S O N S C I E N T I F I C
Copyright 2008 Thomson Corporation 17
T H O M S O N S C I E N T I F I C
What’s Next?
• Release 2008.1: Integrity Predictive Pharmacology Module
– Collection of molecular properties and predictive pharmacology data accessible through visualization tools aimed at expanding existing knowledge within the system
– Separately licensed add-on to Integrity
Copyright 2008 Thomson Corporation 18
T H O M S O N S C I E N T I F I C
Key Bottlenecks in Pharma R&D
PredictivePharmacology
PredictiveToxicology
Identification ofBiomarkers
PatientRecruitment
Validation ofBiomarkers
Risk assessmentwith regulatory
authorities
Copyright 2008 Thomson Corporation 19
T H O M S O N S C I E N T I F I C
Predictive Pharmacology Module
• Why “Predictive Pharmacology”?– Pharmacology: studies the effects of drug activity on biological systems– Predictive Pharmacology attempts to elucidate the behavior of bioactive
compounds — behavior not originally considered by the inventor
• Benefits of Predictive Pharmacology– Rapidly evolving as a key component for increasing drug R&D
productivity by its ability to:• Identify potential new uses for drugs launched or under active
development• Generate new leads faster• Create drug discovery hypotheses
Copyright 2008 Thomson Corporation 20
T H O M S O N S C I E N T I F I C
Copyright 2008 Thomson Corporation 21
T H O M S O N S C I E N T I F I C
Copyright 2008 Thomson Corporation 22
T H O M S O N S C I E N T I F I C
Copyright 2008 Thomson Corporation 23
T H O M S O N S C I E N T I F I C
Copyright 2008 Thomson Corporation 24
T H O M S O N S C I E N T I F I C
Copyright 2008 Thomson Corporation 25
T H O M S O N S C I E N T I F I C
Copyright 2008 Thomson Corporation 26
T H O M S O N S C I E N T I F I C
What Else Is Next?
• New Biomarkers Initiative from Thomson Scientific
Copyright 2008 Thomson Corporation 27
T H O M S O N S C I E N T I F I C
What Is a Biomarker?
• Biomarker: A characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacologic responses to a therapeutic intervention.
From: Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework.
Clin Pharmacol Ther 2001; 69(3): 89-95
Copyright 2008 Thomson Corporation 28
T H O M S O N S C I E N T I F I C
Why Are Biomarkers Important?
• Biomarkers constitute an essential piece in the landscape of modern medicine and may be critical for:
– Validating proof of concept in animal models
– Facilitating early diagnosis and selection for therapy
– Staging disease
– Defining individualized response to drug treatment
– Measuring disease prognosis
– Determining early efficacy
– Monitoring safety
Copyright 2008 Thomson Corporation 29
T H O M S O N S C I E N T I F I C
Our Data Proposition
• Thomson Scientific’s biomarkers initiative will form a single, authoritative and trusted repository of knowledge covering biomarkers in research and in use.
• It will place this knowledge in context, enabling users to assess at a glance the relative importance of different biomarkers.
• Our initiative will expand this to provide a comprehensive, up-to-date body of timely, reliable knowledge on a wide range of biomarkers in different lifecycle phases and disciplines.
Copyright 2008 Thomson Corporation 30
T H O M S O N S C I E N T I F I C
Our Data Proposition
• Biomarker records will include:– Biomarker name(s)
– Classification
– Biological entities / process involved
– Associated drugs
– Role or utility
– Pipeline status
– Validity
– Measurement techniques
– Diagnostic kits (where available)